Predictors of metabolic syndrome in community-dwelling older adults

Jeanine M. Van Ancum, Nini H. Jonkman, Natasja M. van Schoor, Emily Tressel, Carel G. M. Meskers, Mirjam Pijnappels, Andrea B. Maier

1 Department of Human Movement Sciences, @AgeAmsterdam, Vrije Universiteit Amsterdam, Amsterdam Movement Sciences, Amsterdam, The Netherlands, 2 Amsterdam Public Health Research Institute, Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, The Netherlands, 3 Department of Rehabilitation Medicine, VU University Medical Center, Amsterdam Movement Sciences, Amsterdam, the Netherlands, 4 Department of Medicine and Aged Care, @AgeMelbourne, Royal Melbourne Hospital, University of Melbourne, Melbourne, Victoria, Australia

* andrea.maier@mh.org.au

Abstract

Objectives
The metabolic syndrome has been associated with a variety of individual variables, including demographics, lifestyle, clinical measures and physical performance. We aimed to identify independent predictors of the prevalence and incidence of metabolic syndrome in a large cohort of older adults.

Methods
The Longitudinal Aging Study Amsterdam is a prospective cohort including community-dwelling adults aged 55–85 years. Metabolic syndrome was defined according to criteria of the National Cholesterol Education Program Adult Treatment Panel III. The incidence of metabolic syndrome was calculated over a period of three years. Stepwise backward logistic regression analyses were used to identify predictors, including variables for demographics, lifestyle, clinical measures and physical performance, both in a cross-sectional cohort (n = 1292) and a longitudinal sub-cohort (n = 218).

Results
Prevalence and incidence of metabolic syndrome were 37% (n = 479) and 30% (n = 66), respectively. Cross-sectionally, heart disease (OR: 1.91, 95% CI: 1.37–2.65), peripheral artery disease (OR: 2.13, 95% CI: 1.32–3.42), diabetes (OR: 4.74, 95% CI: 2.65–8.48), cerebrovascular accident (OR: 1.92, 95% CI: 1.09–3.37), and a higher Body Mass Index (OR: 1.32, 95% CI: 1.26–1.38) were significant independent predictors of metabolic syndrome. Longitudinally, Body Mass Index (OR: 1.16, 95% CI: 1.05–1.27) was an independent predictor of metabolic syndrome.

Conclusion
Four age related diseases and a higher Body Mass Index were the only predictors of metabolic syndrome in the cross-sectional cohort, despite the large variety of variables included.
in the multivariable analysis. In the longitudinal sub-cohort, a higher Body Mass Index was predictive of developing metabolic syndrome.

Introduction
Metabolic syndrome (MetS) is defined as the coexistence of abdominal obesity, atherogenic dyslipidaemia, high blood pressure and insulin resistance [1]. MetS is highly prevalent in older adults [2], and has been associated with negative health related outcomes, such as a higher risk of cardiovascular morbidity and mortality [3], decline in mobility [4–6], functional dependence [7], and poorer quality of life [7]. MetS is regarded as a pre-disease state, a warning sign for upcoming multimorbidity [8]. Early risk identification of MetS would allow for targeted interventions to prevent future deterioration of the health status.

Previous studies in adults with a mean age range of 37 to 60 years showed multivariable cross-sectional relations of MetS, including smoking [9, 10], alcohol consumption [10, 11], high body fat levels [12], low socioeconomic status [10, 13], feeling stressed [14] and living with family members [9]. Cross-sectional studies in older adults investigated univariable predictors of MetS, but did not perform multivariable analyses [15–22]. Various variables were predictive of MetS in older adults, including lifestyle and physical performance measures [15–22], which the present study combined in multivariable analyses. Longitudinal studies including adults with a mean age range of 39 to 54 years addressed potential independent predictors of the development of MetS, and revealed age [23, 24], Body Mass Index (BMI) [23–25], waist circumference [26, 27], blood pressure [24, 25], insulin resistance [24, 25, 27] and cholesterol levels [24–27] as predictors of MetS incidence. Predictors for the existence and development of MetS in higher chronological age groups might be different, but evidence is lacking. The prevalence of MetS increases with age [2], and components of MetS differ compared to younger age groups [28], therefore, the present study included a cohort of 65 years and older.

The aim of this study was to identify independent predictors of MetS prevalence in a cross-sectional cohort of community-dwelling older adults and to identify independent predictors of MetS incidence at three years follow-up in a longitudinal sub-cohort. We investigated a large variety of variables, including demographics, lifestyle, clinical measures and physical performance.

Methods
Study population
The Longitudinal Aging Study Amsterdam (LASA) is an ongoing longitudinal cohort study with the primary aim to determine predictors, trajectories and consequences of physical, cognitive, emotional and social functioning in relation to ageing. The study started in 1992 in three regions (Zwolle, Oss and Amsterdam) in the Netherlands, and included 3107 community-dwelling participants aged 55–85 years. Participants were recruited from municipal registries, and the oldest old and older men were oversampled. No exclusion criteria were applied. Follow-up assessment cycles are performed every three years, encompassing a main interview with research staff, a medical interview and a self-administered questionnaire. Extended information on the sample and data collection can be found elsewhere [29].

In the present study, we included data from the assessment cycles of 1992 and 1995. Blood samples were only obtained from respondents who participated in the medical interview, and who were aged 65 years and older. For the cross-sectional analyses, data of the 1995 cycle
(n = 1292) were used as in this cycle all five components of MetS were measured. For the longitudinal analyses, a sub-cohort of the 1992 cycle was used including participants at one of the collaborating centres (Zwolle, the Netherlands). Only participants in whom MetS was not prevalent at baseline in 1992 were included in the longitudinal analyses (n = 218). Fig 1 shows a flowchart of the inclusion of participants. The LASA study was approved by the medical ethics committee of the VU University medical center. All participants signed written informed consent.

Possible predictors of MetS

Four groups of variables, including demographics, lifestyle, clinical measures and physical performance, were tested as independent predictors of MetS in the cross-sectional and longitudinal analyses.

Demographics included sex, age, living status, educational level, income and occupational status. Sex and age were derived from registries. Living status was assessed by asking participants if they were living alone or not. Educational level was defined as total years of education and divided into three categories: primary education or lower, secondary education and higher education. Income was self-reported and categorized into four groups: low (f < 1.750), moderate-low (f1.751–2.250), moderate-high (f2.251–3.500) and high income (f > 3.500). Occupational status was assessed by asking participants if they were retired or not.

Lifestyle included smoking status, alcohol consumption and self-reported physical activity. Smoking status was defined as currently smoking or not. Alcohol consumption was reported as number of glasses alcohol consumed per week. The self-reported physical activity was assessed with the LASA Physical Activity Questionnaire (LAPAQ) [30]. The LAPAQ is a validated questionnaire based on seven activities (walking outdoors, bicycling, gardening, light household, heavy household, and up to two sports activities). Participants were asked how often and for how long in the previous two weeks they engaged in each activity. We categorized the score on the LAPAQ into quartiles (quartile 1–4).

Clinical measures composed of cognitive functioning, depressive symptoms, chronic diseases, medication and BMI. Cognitive functioning was measured with the Mini–Mental State
Examination (MMSE) [31]. Depressive symptoms were measured with the Centre for Epidemiologic Studies Depression Scale (CES-D) [32]. Chronic diseases were self-reported and included chronic non-specific lung disease, heart disease, peripheral artery disease, diabetes, cerebrovascular accident (CVA), arthritis and cancer. Self-reported medication use was divided into two groups with a cut-off based on polypharmacy, i.e. exceeding four medications [33]. BMI was calculated with height measured to the nearest 0.001 m using a stadiometer, and weight measured to the nearest 0.1 kg using a calibrated bathroom scale, in kg/m$^2$.

Physical performance composed of the cardigan test, five-times sit-to-stand (STS) test and gait speed. The cardigan test was assessed with the time in seconds required to put on and take off a cardigan. During the five-times STS test participants were asked to stand up from a sitting position and sit down five times at usual pace with their arms folded across their chest, with time recorded in seconds. Gait speed was measured by recording the time required to walk three meters, to turn around and walk back three meters as quickly as possible and converting this to speed in m/s.

**MetS components**

MetS was defined according to the National Cholesterol Education Program Adult Treatment Panel III [1]. The following components were measured in the 1995 cycle: 1) Abdominal obesity (waist circumference $>102$ cm in men or $>88$ cm in women) was measured to the nearest 0.1 cm midway between the lower rib margin and the iliac crest following a normal expiration. 2) High triglycerides ($\geq 1.7$ mmol/L), 3) low high-density lipoprotein (HDL) ($<1.0$ mmol/L in men or $<1.3$ mmol/L in women), and 4) high serum fructosamine ($\geq 247$ μmol/L or use of antidiabetic medication). Triglycerides, HDL and fructosamine were determined by an enzymatic colorimetric test (Roche diagnostics, Mannheim, Germany), performed in EDTA plasma samples stored at –80˚ C at the Department of Clinical Chemistry of the VU University Medical Center (VUmc) in Amsterdam. 5) High blood pressure ($\geq 160/90$ mmHg or use of antihypertensive medication) was measured in sitting position using a standard mercury sphygmomanometer (Omron HEM 706) at the upper arm. Participants were considered to have MetS when $\geq$ three out of five components were present [1].

In the 1992 cycle MetS was based on four components, not including fructosamine. Therefore, at this assessment cycle participants were considered to have MetS when $\geq$ three out of four components where present. Triglycerides and HDL were determined by the enzymatic colorimetric test (Hitachi 717, CHOD-PAP), performed at the ISALA clinic in Zwolle. Blood pressure was measured using an automatic Omron device (Omron HEM 815F) at the finger. Other components were measured as in the 1995 cycle.

**Statistical analyses**

Descriptive statistics of variables were presented as number with % for categorical variables, mean with standard deviation (SD) for normally distributed variables and median with interquartile range (IQR) for skewed variables. Linearity of continuous variables was assessed with logistic regression using dummy variables of quartiles. In case of increasing or decreasing odds ratio’s (OR) in similar direction, the independent variable was assumed to be linearly associated with the outcome [34]. If the linearity assumption was not met, the variable was categorized in tertiles or quartiles.

For the cross-sectional analyses, we performed univariable and multivariable logistic regression analyses. For all univariable analyses, the OR, 95% confidence interval (CI) and p-value (Wald test) were estimated. Variables with a p-value $<0.2$ in the univariable analyses were selected and included in a multivariable logistic regression. A stepwise backwards selection
procedure was applied, until all remaining independent predictors had a p-value <0.05. The explained variance of the multivariable model was reported using Nagelkerke’s $R^2$.

The same method was applied in the longitudinal analyses for identifying predictors of MetS incidence at three years follow-up. Selection bias of participants included in the longitudinal sub-cohort (n = 218) compared to the participants without measurement of MetS (n = 962), was investigated using Independent-Samples T Test (normal distribution), Mann-Whitney U test (skewed distribution) or Chi-square test (categorical variables). Differences were considered statistically significant if $p<0.05$. The Statistical Package for the Social Sciences was used for all analyses (IBM SPSS Statistics for Windows, Version 23.0. Armonk, NY, IBM Corp).

Results

Detailed characteristics of the cross-sectional cohort and longitudinal sub-cohort can be found in Table 1. The percentage of participants diagnosed with MetS in 1995 was 37% (n = 479). The components of MetS were prevalent in 52% of the participants for abdominal obesity, 31% for high triglycerides, 36% for low HDL, 63% for high blood pressure and 25% for high serum fructosamine. Prevalence of medication use was 5% for antilipemics, 33% for antihypertensives and 6% for antidiabetics. Of the participants diagnosed with MetS, 58% were female and the mean age was 75.7 (SD 6.6) years. The percentage of participants developing MetS over three years was 30% (n = 66), of which 49% was female and a mean age was 71.2 (SD 6.2) years.

Cross-sectional analyses

In the univariable analyses, statistically significant associations with Mets were found for female sex, living alone, lower education, lower income, lower alcohol consumption, having a heart disease, peripheral artery disease, diabetes, CVA, osteoarthritis or rheumatoid arthritis, polypharmacy, higher BMI, lower cognition, longer duration of the cardigan test, longer duration of the five-times STS test and lower gait speed (Table 2). The multivariable analysis resulted in five variables to be independent predictors of MetS prevalence in the cross-sectional cohort of community-dwelling older adults: heart disease (OR: 1.91, 95% CI: 1.37–2.65), peripheral artery disease (OR: 2.13, 95% CI: 1.32–3.42), diabetes (OR: 4.74, 95% CI: 2.65–8.48), CVA (OR: 1.92, 95% CI: 1.09–3.37), and a higher BMI (OR: 1.32, 95% CI: 1.26–1.38). The overall explained variance of the multivariable model $R^2$ was 31%.

Longitudinal analyses

S1 Table shows the comparison between participants that were included in the longitudinal sub-cohort (n = 218) and the participants without measurement of MetS (n = 962). The longitudinal sub-cohort was younger and healthier, with lower prevalence of polypharmacy and better physical performance, compared to the entire cohort. In the univariable analyses, living alone (OR: 1.95, 95% CI: 1.05–3.61) and a higher BMI (OR: 1.19, 95% CI: 1.09–1.30) were statistically significant predictors of MetS incidence in the longitudinal sub-cohort of community-dwelling older adults (Table 3). In the multivariable analysis, a higher BMI remained a statistically significant predictor (OR: 1.16, 95% CI: 1.05–1.27). The overall explained variance of the multivariable model resulted in an $R^2$ of 11%.

Discussion

When exploring independent predictors of MetS prevalence in the cross-sectional cohort of community-dwelling older adults, presence of a heart disease, peripheral artery disease,
Table 1. Characteristics of the cross-sectional cohort and the longitudinal sub-cohort.

| Variables                  | Cross-sectional cohort (n = 1292) | Longitudinal sub-cohort (n = 218) |
|----------------------------|----------------------------------|-----------------------------------|
|                            | N MetS prevalence<sup>a</sup>     | N MetS incidence<sup>b</sup>      |
|                            | No (n = 813)                     | Yes (n = 479)                     |
|                            | 218                              | 32 (48.5)                         |
| Demographics               | 198                              | 32 (48.5)                         |
| Sex, female                | 1292                             | 300 (37.0)                        |
| Age, years, mean (SD)      | 75.3 (6.5)                       | 75.7 (6.6)                        |
| Living status, living alone| 308 (37.9)                       | 214 (44.7)                        |
| Education                  | 112 (13.8)                       | 42 (8.8)                          |
| Primary                    | 537                              | 237 (49.5)                        |
| Secondary                  | 599                              | 200 (41.8)                        |
| Higher                     | 154                              | 84                                |
| Income                     | 308 (37.9)                       | 214 (44.7)                        |
| Low                        | 285                              | 126 (29.1)                        |
| Moderate-low               | 286                              | 111 (25.6)                        |
| Moderate-high              | 342                              | 123 (28.4)                        |
| High                       | 276                              | 73 (16.9)                         |
| Retired                    | 752 (94.7)                       | 448 (96.3)                        |
| Lifestyle                  | 160 (19.7)                       | 74 (15.4)                         |
| Current smoking            | 1292                             | 2 (0–7)                           |
| Alcohol, units/week, median (IQR) | 1291                            | 217                               |
| LAPAQ                      | 311                              | 2 (0–7)                           |
| Quartile 1                 | 1291                             | 217                               |
| Quartile 2                 | 312                              | 2 (0–7)                           |
| Quartile 3                 | 319                              | 2 (0–7)                           |
| Quartile 4                 | 301                              | 2 (0–7)                           |
| Clinical                   | 28 (15.4)                        | 38 (25.2)                         |
| MMSE, median (IQR)         | 1292                             | 1 (0–10)                          |
| CES-D, median (IQR)        | 1291                             | 2 (0–7)                           |
| Chronic diseases           | 64 (13.4)                        | 39 (25.8)                         |
| Pulmonary disease          | 1291                             | 15 (25.0)                         |
| Heart disease              | 1291                             | 15 (25.0)                         |
| Peripheral artery disease  | 1291                             | 15 (25.0)                         |
| Diabetes                   | 1291                             | 15 (25.0)                         |
| CVA                        | 1291                             | 15 (25.0)                         |
| OA or RA                   | 1291                             | 15 (25.0)                         |
| Cancer                     | 1291                             | 15 (25.0)                         |
| Polyparmacy                | 1291                             | 15 (25.0)                         |
| BMI, kg/m<sup>2</sup>, mean (SD) | 1291                            | 15 (25.0)                         |
| Physical performance       | 28 (15.4)                        | 34 (22.5)                         |
| Cardigan test, sec, mean (SD) | 1291                            | 40 (26.5)                         |
| 5-times STS test, sec, mean (SD) | 1291                            | 14 (21.5)                         |
| Gait speed, meter/sec, mean (SD) | 1291                            | 14 (21.5)                         |
| MetS components            | 1291                             | 14 (21.5)                         |
| BP, mmHg, mean (SD)        | 1291                             | 14 (21.5)                         |
| Systolic                   | 1271                             | 149.9 (24.9)                      |
| Diastolic                  | 1271                             | 146.0 (24.0)                      |
| WC, cm, mean (SD)          | 614                              | 105.2 (8.4)                       |
| Males                      | 1263                             | 102 (6.7)                         |
| Females                    | 627                              | 98 (6.7)                          |
| Triglycerides, mmol/L, mean (SD) | 1291                            | 1.8 (0.8)                         |
| Males                      | 1291                             | 2.1 (0.9)                         |
| Females                    | 627                              | 1.8 (0.8)                         |
| HDL, mmol/L, mean (SD)     | 1291                             | 3.7 (1.0)                         |
| Males                      | 1291                             | 3.7 (1.0)                         |
| Females                    | 627                              | 3.7 (1.0)                         |
| LDL, mmol/L, mean (SD)     | 1291                             | 4.0 (1.1)                         |
| Males                      | 1291                             | 4.0 (1.1)                         |
| Females                    | 627                              | 4.0 (1.1)                         |

<sup>a</sup>Mean (SD), <sup>b</sup>Median (IQR).
diabetes, CVA and a higher BMI were predictive of MetS. A higher BMI was an independent predictor of MetS incidence at three years follow-up in the longitudinal sub-cohort.

We expected that the predictors of MetS would consist of a variety of variables, including demographics, lifestyle, clinical measures, and physical performance. However, only five predictors of MetS prevalence were identified in the cross-sectional cohort, and only one predictor was identified in the longitudinal cohort. Due to the low number of predictors, the explained variance of the models was low. Prediction of the development of MetS in older adults is complex, which may be due to the multifactorial nature of MetS: MetS consists of multiple components. When applying the diagnostic cut-off of three out of five MetS components to the population, a heterogeneous cohort is composed [35]. This composed population could also explain the complex prediction of MetS, and the relatively low $R^2$ observed for both the cross-sectional and longitudinal multivariable models.

We reported a set of common comorbidities, heart disease, peripheral artery disease, diabetes and CVA to be predictors of MetS prevalence in the cross-sectional cohort of community-dwelling older adults. As MetS is a precursor of these comorbidities [3], it is likely that participants first developed MetS and subsequently got diagnosed with the related diseases. This is also supported by our multivariable longitudinal analysis in which the comorbidities were not identified as predictors of MetS incidence.

In the multivariable cross-sectional analysis, a higher BMI remained an independent predictor of MetS. Our findings build upon two previous studies showing in univariable analyses that older adults with MetS have higher levels of BMI [15, 16]. Moreover, a higher BMI as well as obesity are well-known predictors of components of MetS, including hypertension, dyslipidemia and diabetes [36, 37].

In concordance with the cross-sectional analysis, the longitudinal multivariable analysis did not provide multiple predictors of MetS incidence. In fact, only a higher BMI was found to be predictive of MetS, during a follow-up of three years. Applying lifestyle modifications for 12 months has shown to reduce body weight, lower BMI, and subsequently prevent the development of MetS [38]. In line with our results, previous studies in younger adults identified BMI as a predictor of MetS incidence in longitudinal cohorts [23–25]. Since this finding of BMI as a longitudinal independent predictor is supported by our cross-sectional analysis and previous literature [23–25], we would speculate that a higher BMI precedes MetS. This in turn leads to a deterioration of the health status. Previous studies in younger adults identified BMI cut-off values up to 25.5 kg/m2 to be best associated with MetS prevalence [39, 40]. At older age, a shift occurs in the cut-off values for some of the components of MetS [41]. Therefore, the optimal cut-off value for BMI to predict

### Table 1. (Continued)

| Variables                      | Cross-sectional cohort (n = 1292) | Longitudinal sub-cohort (n = 218) |
|-------------------------------|----------------------------------|----------------------------------|
|                               | N  | MetS prevalence a | N  | MetS incidence b |
|                               |    |                  |    |                  |
|                               | No (n = 813) | Yes (n = 479) | No (n = 152) | Yes (n = 66) |
| Fructosamine, μmol/L, mean (SD) | 1289 | 227.8 (29.9) | 248.5 (45.6) | – | – |

All variables are presented as n (%) unless indicated otherwise. BMI: Body Mass Index, BP: Blood Pressure, CES-D: Centre for Epidemiologic Studies-Depression Scale, CVA: Cerebrovascular Accident, HDL: High-Density Lipoprotein cholesterol, IQR: Interquartile Range, LAPAQ: LASA Physical Activity Questionnaire, MetS: Metabolic Syndrome, MMSE: Mini–Mental State Examination, N: Number of participants, OA: Osteoarthritis, RA: Rheumatoid Arthritis, SD: Standard Deviation, STS: Sit-To-Stand, WC: Waist circumference.

* MetS prevalence: baseline values T1 (1995).
* MetS incidence: baseline values T0 (1992–1995).
* Not reported as this variable was not measured in 1992.

https://doi.org/10.1371/journal.pone.0206424.t001
MetS is likely to be higher in older adults, but this should be investigated in larger longitudinal studies. Screening adults with a higher BMI for MetS should be emphasized.

**Strengths and limitations**

This is the first study to investigate in a representative sample of community-dwelling older adults a large variety of independent predictors of MetS. However, some limitations are worth discussing. First, we included variables based on questionnaires, like the LAPAQ physical activity questionnaire. Objective physical activity monitoring with accelerometers might have provided a more accurate prediction of MetS. Possible effects of underlying morbidity and

---

Table 2. Potential predictors of MetS prevalence in the cross-sectional cohort of community-dwelling older adults.

| Variables | Univariable | Multivariable |
|-----------|------------|---------------|
|           | Odds Ratio | 95% CI | p-value | Odds Ratio | 95% CI | p-value |
| Demographics | | | | | | |
| Sex, female | 1.55 | 1.23–1.94 | <0.001 | | | |
| Age, years | 1.01 | 0.99–1.03 | 0.21 | | | |
| Living status, living alone | 1.32 | 1.05–1.67 | 0.02 | | | |
| Education | | | | | | |
| Primary vs higher | 2.11 | 1.42–3.12 | <0.001 | | | |
| Secondary vs higher | 1.34 | 0.90–1.98 | 0.15 | | | |
| Income | | | | | | |
| Low vs high | 2.20 | 1.55–3.14 | <0.001 | | | |
| Moderate-low vs high | 1.76 | 1.23–2.52 | <0.01 | | | |
| Moderate-high vs high | 1.56 | 1.10–2.21 | 0.01 | | | |
| Retired | 1.47 | 0.83–2.62 | 0.19 | | | |
| Lifestyle | | | | | | |
| Current smoking | 0.75 | 0.55–1.01 | 0.06 | | | |
| Alcohol, units/week | 0.98 | 0.97–0.99 | 0.001 | | | |
| LAPAQ, quartiles | | | | | | |
| 1 vs 4 | 1.37 | 0.98–1.90 | 0.06 | | | |
| 2 vs 4 | 0.98 | 0.70–1.36 | 0.89 | | | |
| 3 vs 4 | 1.22 | 0.88–1.70 | 0.23 | | | |
| Clinical measures | | | | | | |
| MMSE | 0.95 | 0.92–0.99 | 0.01 | | | |
| CES-D | 1.00 | 0.98–1.01 | 0.84 | | | |
| Chronic Diseases | | | | | | |
| Pulmonary disease | 0.84 | 0.61–1.16 | 0.29 | | | |
| Heart disease | 1.68 | 1.31–2.16 | <0.001 | 1.91 | 1.37–2.65 | <0.001 |
| Peripheral artery disease | 2.13 | 1.50–3.04 | <0.001 | 2.13 | 1.32–3.42 | 0.002 |
| Diabetes | 5.48 | 3.48–8.64 | <0.001 | 4.74 | 2.65–8.48 | <0.001 |
| CVA | 2.43 | 1.60–3.68 | <0.001 | 1.92 | 1.09–3.37 | 0.024 |
| OA or RA | 1.21 | 0.97–1.52 | <0.001 | | | |
| Cancer | 1.19 | 0.84–1.68 | 0.34 | | | |
| Polypharmacy | 2.31 | 1.71–3.10 | <0.001 | | | |
| BMI, kg/m² | 1.26 | 1.22–1.31 | <0.001 | 1.32 | 1.26–1.38 | <0.001 |
| Physical performance | | | | | | |
| Cardigan test, sec | 1.03 | 1.01–1.04 | 0.01 | | | |
| 5-times STS test, sec | 1.03 | 1.01–1.06 | 0.01 | | | |
| Gait speed, meter/sec | 0.40 | 0.26–0.63 | <0.001 | | | |

95% CI: 95% confidence interval, BMI: Body Mass Index, CES-D: Centre for Epidemiologic Studies-Depression Scale, CVA: Cerebrovascular Accident, HDL: High-Density-Lipoprotein, IQR: Interquartile Range, LAPAQ: LASA Physical Activity Questionnaire, MetS: Metabolic Syndrome, MMSE: Mini–Mental State Examination, N: Number of participants, OA: Osteoarthritis, RA: Rheumatoid Arthritis, SD: Standard Deviation, STS: Sit-To-Stand.

https://doi.org/10.1371/journal.pone.0206424.t002
The prevalence of triglycerides, HDL and fructosamine was based on a single blood assessment, which may have introduced misclassification bias. Furthermore, the longitudinal analyses were limited by a smaller sample size and discrepancies in the sequential measurements of the components of MetS in 1992 and 1995. The subcohort was slightly younger and healthier compared to participants not included in the longitudinal analyses. This possible selection bias of participants might have caused an underestimation of MetS incidence after three years follow-up. However, the independent predictor identified in the longitudinal analysis is in line with the multivariable cross-sectional analysis.

### Table 3. Potential predictors of MetS incidence at three years follow-up in the longitudinal sub-cohort of community-dwelling older adults.

| Variables                  | Odds Ratio | 95% CI | p-value |
|----------------------------|------------|--------|---------|
| Demographics               |            |        |         |
| Sex, female                | 1.23       | 0.69–2.19 | 0.49   |
| Age, years                 | 1.00       | 0.95–1.04 | 0.91   |
| Living status, living alone| 1.95       | 1.05–3.61 | 0.03   |
| Education                  |            |        |         |
| Primary vs higher          | 1.30       | 0.51–3.30 | 0.58   |
| Secondary vs higher        | 1.17       | 0.47–2.91 | 0.74   |
| Income                     |            |        |         |
| Low vs high                | 1.39       | 0.59–3.26 | 0.45   |
| Moderate-low vs high       | 2.16       | 0.86–5.43 | 0.10   |
| Moderate-high vs high      | 1.36       | 0.56–3.30 | 0.50   |
| Retired                    | 2.31       | 0.76–7.05 | 0.14   |
| Lifestyle                  |            |        |         |
| Current smoking            | 0.89       | 0.41–1.91 | 0.76   |
| Alcohol, units/week        | 0.99       | 0.95–1.03 | 0.56   |
| LAPAQ, quartiles           |            |        |         |
| 1 vs 4                     | 1.20       | 0.52–2.80 | 0.67   |
| 2 vs 4                     | 1.10       | 0.47–2.58 | 0.83   |
| 3 vs 4                     | 1.68       | 0.74–3.82 | 0.22   |
| Clinical measures          |            |        |         |
| MMSE                       | 1.11       | 0.95–1.29 | 0.20   |
| CES-D                      | 1.01       | 0.97–1.05 | 0.75   |
| Chronic Diseases           |            |        |         |
| Pulmonary disease          | 0.97       | 0.40–2.33 | 0.94   |
| Heart disease              | 1.25       | 0.61–2.57 | 0.55   |
| Peripheral artery disease  | 1.52       | 0.56–4.11 | 0.41   |
| Diabetes                   | 2.00       | 0.59–6.78 | 0.27   |
| CVA                        | 0.92       | 0.17–4.86 | 0.92   |
| OA or RA                   | 1.21       | 0.66–2.20 | 0.54   |
| Cancer                     | 0.88       | 0.30–2.57 | 0.81   |
| Polypharmacy               | 2.89       | 0.85–9.83 | 0.09   |
| BMI, kg/m²                 | 1.19       | 1.09–1.30 | <0.001* |
| Physical performance       |            |        |         |
| Cardigan test, sec         | 1.01       | 0.96–1.07 | 0.70   |
| 5-times STS test, sec      | 1.04       | 0.98–1.11 | 0.21   |
| Gait speed, meter/sec      | 0.47       | 0.18–1.20 | 0.11   |

95% CI: 95% confidence interval, BMI: Body Mass Index, CES-D: Centre for Epidemiologic Studies-Depression Scale, CVA: Cerebrovascular Accident, HDL: High-Density-Lipoprotein, IQR: Interquartile Range, LAPAQ: LASA Physical Activity Questionnaire, MetS: Metabolic Syndrome, MMSE: Mini–Mental State Examination, N: Number of participants, OA: Osteoarthritis, RA: Rheumatoid Arthritis, SD: Standard Deviation, STS: Sit-To-Stand.

* BMI remains significant after multivariable analysis: Odds 1.16, 95% CI 1.05–1.27, p-value 0.002.

https://doi.org/10.1371/journal.pone.0206424.t003
and could provide a relevant component for future screening tools of MetS in older adults. Larger longitudinal studies in older adults are needed to confirm our findings, and prospective population-based studies are needed to investigate the mechanisms behind these findings.

**Conclusion**

Cross-sectionally, heart disease, peripheral artery disease, diabetes, CVA and a higher BMI were the only predictors of MetS prevalence in community-dwelling older adults, despite the large variety of variables included in the multivariable analysis. A higher BMI was predictive of MetS incidence at three years follow-up in a longitudinal sub-cohort of older adults. A higher BMI is already recognized as an important risk factor for age related disease in primary care, but should also be used as identifier of older adults at risk for development of MetS.

**Supporting information**

S1 Table. Characteristics of participants that were included in the longitudinal sub-cohort (n = 218), and participants without measurement of MetS (n = 962). All variables are presented as n (%) unless indicated otherwise. BMI: Body Mass Index, BP: Blood Pressure, CES-D: Centre for Epidemiologic Studies-Depression Scale, CVA: Cerebrovascular Accident, HDL: High-Density Lipoprotein cholesterol, IQR: Interquartile Range, LAPAQ: LASA Physical Activity Questionnaire, MetS: Metabolic Syndrome, MMSE: Mini–Mental State Examination, N: Number of participants, OA: Osteoarthritis, RA: Rheumatoid Arthritis, SD: Standard Deviation, STS: Sit-To-Stand, WC: Waist circumference. * Statistically significant different compared to participants without measurement of MetS (p<0.05).

**Author Contributions**

**Conceptualization:** Jeanine M. Van Ancum, Nini H. Jonkman, Natasja M. van Schoor, Emily Tressel, Carel G. M. Meskers, Mirjam Pijnappels, Andrea B. Maier.

**Data curation:** Natasja M. van Schoor.

**Formal analysis:** Jeanine M. Van Ancum, Nini H. Jonkman, Emily Tressel.

**Funding acquisition:** Natasja M. van Schoor, Andrea B. Maier.

**Methodology:** Jeanine M. Van Ancum, Nini H. Jonkman, Emily Tressel, Carel G. M. Meskers, Mirjam Pijnappels, Andrea B. Maier.

**Project administration:** Natasja M. van Schoor.

**Supervision:** Carel G. M. Meskers, Mirjam Pijnappels, Andrea B. Maier.

**Writing – original draft:** Jeanine M. Van Ancum, Nini H. Jonkman, Emily Tressel, Carel G. M. Meskers, Mirjam Pijnappels, Andrea B. Maier.

**Writing – review & editing:** Jeanine M. Van Ancum, Nini H. Jonkman, Natasja M. van Schoor, Carel G. M. Meskers, Mirjam Pijnappels, Andrea B. Maier.

**References**

1. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106(25):3143–421. PMID: 12485966
2. Kolovou GD, Anagnostopoulou KK, Salpea KD, Mikhailidis DP. The prevalence of metabolic syndrome in various populations. Am J Med Sci. 2007; 333(6):362–71. https://doi.org/10.1097/MAJ.0b013e318065ca3a PMID: 17570989

3. Mottillo S, Filion KB, Genest J, Joseph L, Pilotte L, Poirier P, et al. The metabolic syndrome and cardiovascular risk: a systematic review and meta-analysis. J Am Coll Cardiol. 2010; 56(14):1113–32. https://doi.org/10.1016/j.jacc.2010.05.034 PMID: 20863953

4. Blazer DG, Hybels CF, Fillenbaum GG. Metabolic syndrome predicts mobility decline in a community-based sample of older adults. J Am Geriatr Soc. 2006; 54(3):502–6. https://doi.org/10.1111/j.1532-5415.2005.00607.x PMID: 16551320

5. Penninx BW, Nicklas BJ, Newman AB, Harris TB, Goodpaster BH, Satterfield S, et al. Metabolic syndrome and physical decline in older persons: results from the Health, Aging And Body Composition Study. J Gerontol A Biol Sci Med Sci. 2009; 64(1):96–102. https://doi.org/10.1093/gerona/ghn005 PMID: 19164274

6. Carrie I, Peres K, Ancelin ML, Gourlet V, Berr C, Barberger-Gateau P, et al. Metabolic syndrome and disability: findings from the prospective three-city study. J Gerontol A Biol Sci Med Sci. 2014; 69(1):79–86. https://doi.org/10.1093/gerona/glt101 PMID: 23833203

7. Roriz-Cruz M, Rosset I, Wada T, Sakagami T, Ishine M, Roriz-Filho JS, et al. Stroke-independent association between metabolic syndrome and functional decline, depression, and low quality of life in elderly community-dwelling Brazilian people. J Am Geriatr Soc. 2007; 55(3):374–82. https://doi.org/10.1111/j.1532-5415.2007.01068.x PMID: 17341239

8. Tsai SP, Wen CP, Chan HT, Chang YJ, Tsai MK, Cheng TY. The effects of pre-disease risk factors within metabolic syndrome on all-cause and cardiovascular disease mortality. Diabetes Res Clin Pract. 2008; 82(1):148–56. https://doi.org/10.1016/j.diabres.2008.07.016 PMID: 18757109

9. Yu M, Xu CX, Zhu HH, Hu RY, Zhang J, Wang H, et al. Associations of cigarette smoking and alcohol consumption with metabolic syndrome in a male Chinese population: a cross-sectional study. J Epidemiol. 2014; 24(5):361–9. https://doi.org/10.2188/jea.JE20130112 PMID: 24910131

10. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988–1994. Arch Intern Med. 2003; 163(4):427–36. PMID: 12588201

11. Yang EJ, Lim S, Lim JY, Kim KW, Jang HC, Paik NJ. Association between muscle strength and metabolic syndrome in older Korean men and women: the Korean Longitudinal Study on Health and Aging. Metabolism. 2012; 61(3):317–24. https://doi.org/10.1016/j.metabol.2011.07.005 PMID: 21871640

12. Bankoski A, Harris TB, McClain JJ, Brychta RJ, Caserotti P, Shen KY, et al. Sedentary activity associated with metabolic syndrome independent of physical activity. Diabetes Care. 2011; 34(2):497–503. https://doi.org/10.2337/dc10-0987 PMID: 21270206

13. Gao X, Nelson ME, Tucker KL. Television viewing is associated with prevalence of metabolic syndrome in Hispanic elders. Diabetes Care. 2007; 30(3):694–700. https://doi.org/10.2337/dc06-1835 PMID: 17327343

14. Wu TT, Chen IJ, Cho SL, Chiou AF. The Relationship Between Health-Promoting Behaviors and Metabolic Syndrome in Community-Dwelling Older Adults. Biol Res Nurs. 2016; 18(5):549–57. https://doi.org/10.1177/1099800416655882 PMID: 27340227

15. Ishii T, Tanaka T, Akihisa M, Ouchi Y, Fujii T, Iijima K. Metabolic syndrome, sarcopenia and role of sex and age: cross-sectional analysis of Kashiwa cohort study. PLoS One. 2014; 9(11):e112718. https://doi.org/10.1371/journal.pone.0112718 PMID: 25405866
21. Kawamoto R, Ninomiya D, Kasai Y, Kusunoki T, Ohtsuka N, Kumagi T, et al. Handgrip strength is associated with metabolic syndrome among middle-aged and elderly community-dwelling persons. Clin Exp Hypertens. 2016; 38(2):245–51. https://doi.org/10.3109/10641963.2015.1081322 PMID: 26818203
22. Sayer AA, Syddall HE, Dennison EM, Martin HJ, Phillips DI, Cooper C, et al. Grip strength and the metabolic syndrome: findings from the Hertfordshire Cohort Study. QJM. 2007; 100(1):707–13. https://doi.org/10.1093/qjmed/hcm195 PMID: 17951315
23. Yang FY, Wahqvist ML, Lee MS. Body mass index (BMI) as a major factor in the incidence of the metabolic syndrome and its constituents in unaffected Taiwanese from 1998 to 2002. Asia Pac J Clin Nutr. 2008; 17(2):339–51. PMID: 18586657
24. Hirose H, Takayama T, Hozawa S, Hibi T, Saito I. Prediction of metabolic syndrome using artificial neural network system based on clinical data including insulin resistance index and serum adiponectin. Comput Biol Med. 2011; 41(11):1051–6. https://doi.org/10.1016/j.compbiomed.2011.09.005 PMID: 22000697
25. Zhang W, Chen Q, Yuan Z, Liu J, Du Z, Tang F, et al. A routine biomarker-based risk prediction model for metabolic syndrome in urban Han Chinese population. BMC Public Health. 2015; 15:64. https://doi.org/10.1186/s12889-015-1424-z PMID: 25637138
26. Hsiao FC, Wu CZ, Hsieh CH, He CT, Hung YJ, Pei D. Chinese metabolic syndrome risk score. South Med J. 2009; 102(2):159–64. https://doi.org/10.1097/SMJ.0b013e318138b619 PMID: 19139715
27. Palaniappan L, Carnethon MR, Wang Y, Hanley AJ, Fortmann SP, Haffner SM, et al. Predictors of the incident metabolic syndrome in adults: the Insulin Resistance Atherosclerosis Study. Diabetes Care. 2004; 27(3):788–93. PMID: 14988303
28. Sumner AD, Sardi GL, Reed JF 3rd. Components of the metabolic syndrome differ between young and old adults in the US population. J Clin Hypertens (Greenwich). 2012; 14(8):502–6.
29. Hoogendijk EO, Deeg DJ, Poppelaars J, van der Horst M, Broese van Groenou MI, Comijs HC, et al. The Longitudinal Aging Study Amsterdam: cohort update 2016 and major findings. Eur J Epidemiol. 2016; 31(9):927–45. https://doi.org/10.1007/s10654-016-0192-0 PMID: 22544533
30. Stel VS, Smit JH, Visscher M, Deeg DJ, Lips P. Comparison of the LASA Physical Activity Questionnaire with a 7-day diary and pedometer. J Clin Epidemiol. 2004; 57(3):252–8. https://doi.org/10.1016/j.jclinepi.2003.07.008 PMID: 15066685
31. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3):189–98. PMID: 1202204
32. Radiolf LS. The CES-D Scale. Appl Psychol Meas. 1977; 1(3):385–401.
33. Gnjidic D, Hilmer SN, Blyth FM, Naganathan V, Waite L, Seibel MJ, et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol. 2012; 65(9):989–95. https://doi.org/10.1016/j.jclinepi.2012.02.018 PMID: 22742913
34. Twisk JWR. [Inleiding in de toegepaste biostatistiek]: Reed Business Education; 2014.
35. Saukkonen T, Jokelainen J, Timonen M, Cederberg H, Laakso M, Harkonen P, et al. Prevalence of metabolic syndrome components among the elderly using three different definitions: a cohort study in Finland. Scand J Prim Health Care. 2012; 30(1):29–34. https://doi.org/10.3109/02813432.2012.654192 PMID: 22324547
36. Brown CD, Higgins M, Donato KA, Rohde FC, Garrison R, Obarzanek E, et al. Body mass index and the prevalence of hypertension and dyslipidemia. Obes Res. 2000; 8(9):605–19. https://doi.org/10.1038/oby.2000.79 PMID: 11225709
37. Alvim Rde O, Mourao-Junior CA, de Oliveira CM, Krieger JE, Mill JG, Pereira AC. Body mass index, waist circumference, body adiposity index, and risk for type 2 diabetes in two populations in Brazil: general and Amerindian. PLoS One. 2014; 9(6):e100223. https://doi.org/10.1371/journal.pone.0100223 PMID: 24937307
38. Bassi N, Karagodin I, Wang S, Vassallo P, Priyanath A, Massaro E, et al. Lifestyle modification for metabolic syndrome: a systematic review. Am J Med. 2014; 127(12):1242.e1–10.
39. Aye M, Sazali M. Waist circumference and BMI cut-off points to predict risk factors for metabolic syndrome among outpatients in a district hospital. Singapore Med J. 2012; 53(8):545–50. PMID: 22941134
40. Kawada T, Otsuka T, Inagaki H, Wakayama Y, Li Q, Li YJ, et al. Optimal cut-off levels of body mass index and waist circumference in relation to each component of metabolic syndrome (MetS) and the number of MetS component. Diabetes Metab Syndr. 2011; 5(1):25–8. https://doi.org/10.1016/j.dsx.2010.05.012 PMID: 22814837
41. Childers DK, Allison DB. The ‘Obesity Paradox’—a parsimonious explanation for relations among obesity, mortality rate, and aging? Int J Obes (Lond). 2010; 34(8):1231–8.
